This resolution affirms that U.S. policy on mifepristone access must respect over 25 years of scientific evidence proving its safety and ensure equitable access based on the best available science.
Diana DeGette
Representative
CO-1
This resolution expresses the sense of the House that policies governing access to mifepristone for medication abortion must be based on over 25 years of proven safety and effectiveness data. It affirms that access to this time-sensitive care should be equitable, transparent, and guided by the best available, peer-reviewed science, not political interference. The bill supports the FDA's authority to regulate based on evidence, including telemedicine and pharmacy dispensing.
House Resolution Backs 25 Years of Science on Mifepristone: A Push for Evidence-Based Medication Access.
This resolution serves as a formal declaration from the House of Representatives that the regulation of mifepristone—a drug used for medication abortions and miscarriage management—should be guided by two decades of medical data rather than political maneuvering. It explicitly highlights that since its FDA approval over 25 years ago, mifepristone has maintained a safety record that outshines many common prescriptions. The resolution aims to protect the current system where healthcare providers can prescribe the medication via telehealth and patients can receive it through certified pharmacies or by mail, ensuring that medical standards, not zip codes, determine healthcare access.
The Science of Safety
For anyone who hasn't spent their weekend reading clinical trials, the bill lays out a compelling case: mifepristone went through a 54-month FDA review before it ever hit the market. Since then, it’s been used by millions and is recognized as an 'essential medicine' by the World Health Organization. Even though it’s safer than many drugs you can get with a standard script, the FDA still regulates it under a specific framework called REMS (Risk Evaluation and Mitigation Strategy). The resolution points out that while the FDA recently modernized these rules in 2021 and 2023 to allow for mail-order and pharmacy pickup, the drug is still more heavily regulated than 99 percent of other prescription medications. For a busy professional or a parent who can’t take a full day off to drive to a distant clinic, these modernized rules are the difference between getting care and being left behind.
Breaking Down the Barriers
The resolution doesn't shy away from the real-world fallout of the 2022 Dobbs decision. It notes that as of May 2024, 20 states have moved to ban or severely restrict abortion, creating a ripple effect of long wait times and increased travel costs. For a worker in a rural community or someone living paycheck to paycheck, a 'simple' medical appointment can become an impossible financial hurdle if it requires an out-of-state trip. The text specifically highlights that these barriers hit marginalized groups the hardest—including Indigenous communities, people with disabilities, and those experiencing domestic violence—who may rely on the privacy and convenience of telehealth to stay safe and healthy.
Protecting the Process
At its core, this is about who gets to make medical decisions. The resolution argues that the FDA was given the authority by Congress to make calls based on 'gold-standard' peer-reviewed science, not political pressure. By acknowledging that medication abortion now accounts for 63 percent of all abortions in the U.S., the House is signaling that the current healthcare infrastructure heavily relies on this drug. If the scientific review process is undermined by lawsuits or misinformation, it doesn't just affect one drug; it sets a precedent that could destabilize how all medications are regulated, potentially impacting everything from your asthma inhaler to your blood pressure meds.